These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22187284)

  • 21. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 23. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 24. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 25. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.
    Carlet J
    Intensive Care Med; 2004 May; 30(5):994; author reply 995. PubMed ID: 15083270
    [No Abstract]   [Full Text] [Related]  

  • 26. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 28. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 29. Should we treat severe sepsis with activated protein C?
    Mackillop A
    Hosp Med; 2003 May; 64(5):316. PubMed ID: 12789748
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 31. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 32. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 33. The authors reply: academic and industry partnerships.
    Goldstein B; Nadel S; Peters M; Barton R; Machado F; Giroir B
    Pediatr Crit Care Med; 2006 May; 7(3):278-9. PubMed ID: 16682889
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of sepsis.
    Khurana A; Vinayek N
    N Engl J Med; 2007 Mar; 356(11):1178-9; author reply 1181-2. PubMed ID: 17366659
    [No Abstract]   [Full Text] [Related]  

  • 35. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 37. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 38. Toll-like receptor 4 modulation as a strategy to treat sepsis.
    Wittebole X; Castanares-Zapatero D; Laterre PF
    Mediators Inflamm; 2010; 2010():568396. PubMed ID: 20396414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.